Fique off-line com o app Player FM !
Podcasts que valem a pena ouvir
PATROCINADO
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2
Manage episode 445409820 series 3389426
touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchONCOLOGY.com
102 episódios
Manage episode 445409820 series 3389426
touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.
The multidisciplinary team
- Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
- Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
- Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
www.touchONCOLOGY.com
102 episódios
Todos os episódios
×1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.